David L. Hallal

Chief executive: Alexion Pharmaceuticals (1 Apr 2015 to 11 Dec 2016)

10commitments announced

7with a clear outcome

6met on time

–rate shown after 15 outcomes

Commitments are credited to the chief executive in office on the day they were announced. Where a deadline fell after the leader left, the entry is marked. Sources for each leadership change: Alexion Pharmaceuticals filing.

Commitments announced under David L. Hallal

Alexion Pharmaceuticalsannounced 27 Oct 2016	Begin enrollment for the ALXN1210 PNH registration trial due after leader left	Met31 Dec 2016
Alexion Pharmaceuticalsannounced 27 Oct 2016	File regulatory submissions for eculizumab for refractory gMG in the U.S. and Europe due after leader left	Met31 Mar 2017
Alexion Pharmaceuticalsannounced 28 Jul 2016	Present additional PNH data for ALXN1210 due after leader left	Met · disputed31 Dec 2016
Alexion Pharmaceuticalsannounced 6 Jun 2016	Present REGAIN study results at the 14th International Congress on Neuromuscular Diseases	Met7 Jul 2016
Alexion Pharmaceuticalsannounced 28 Apr 2016	Present data from the ALXN1210 Phase 1/2 study	Met30 Jun 2016
Alexion Pharmaceuticalsannounced 3 Feb 2016	Present six-month data from the SBC-103 study	Met31 Mar 2016
Alexion Pharmaceuticalsannounced 3 Feb 2016	Report preliminary data from the REGAIN study	No record found30 Jun 2016
Alexion Pharmaceuticalsannounced 3 Feb 2016	Advance four preclinical programs into the clinic due after leader left	No record found31 Dec 2016
Alexion Pharmaceuticalsannounced 3 Feb 2016	Report preliminary data from the PROTECT study due after leader left	No record found31 Dec 2016
Alexion Pharmaceuticalsannounced 3 Feb 2016	Complete enrollment in the PREVENT study due after leader left	Not met31 Dec 2016

Is this record wrong, or are you David L. Hallal? Add a statement or ask for a correction.

Commitments announced under David L. Hallal

The Deadline Report